Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + cytarabine + granulocyte colony-stimulating factor
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
The combination of fludarabine, cytarabine, and granulocyte colony-stimulating factor is known as the FLAG regimen. It is primarily used as a chemotherapy protocol for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), especially in patients who are ineligible for anthracycline-based therapy due to age or comorbidities[2][4][5]. Fludarabine and cytarabine are antimetabolite chemotherapy agents that inhibit DNA synthesis, thereby preventing cancer cell proliferation. Granulocyte colony-stimulating factor (G-CSF) is a biologic growth factor that stimulates bone marrow to produce more neutrophils, aiding recovery from chemotherapy-induced neutropenia[4][5]. The regimen can be administered intravenously for the chemotherapeutics and subcutaneously for G-CSF. FLAG may be used as induction therapy or salvage therapy in relapsed/refractory AML or high-risk MDS[2][8].
- Brand names
- None
- Other names
- Ara-C (for cytarabine)G-CSF (for granulocyte colony-stimulating factor)
02
Targets
POLA1 (DNA polymerase alpha)CSF3R (Granulocyte colony-stimulating factor receptor)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on fludarabine + cytarabine + granulocyte colony-stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + cytarabine + granulocyte colony-stimulating factor.